Development and evaluation of pharmaceutical 3D printability for hot melt extruded cellulose-based filaments

摘要

Polymeric oral controlled dosage development is considered to be an economical and immediate method of drug consumption for reducing the inconvenience caused by the frequent dosing of conventional tablets, and can improve the patients' quality of life (QOL) [1], Moreover, the increased use of additive manufacturing (AM), also as known as three-dimensional (3D) printing technology, has provided a practical solution to the individual and complex consumption of oral controlled drug delivery systems (DDS'). 3D printing is the layer-by-layer production of 3D objects from digital blueprints [2]. This technology is more efficient and economical compared to the development of new active pharmaceutical ingredients or excipients, new manufacturing processes, or protocols. Additionally, 3D printing technology provides an alternative approach toward engineering release profiles by controlling the spatial distribution within a given polymer composition instead of creating a new host material [3].